Praxis, Proqr and Nordic Nanovector are awaiting important data.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
The company is making a high-risk, high-reward bet with the purchase of Gyroscope.
A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.
2022 kicks off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca hopes to extend Lynparza even further.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Data on five patients treated with the Crispr therapy EDIT-101 raise doubts about efficacy and safety.